Recent development of non-peptide GnRH antagonists

38Citations
Citations of this article
32Readers
Mendeley users who have this article in their library.

Abstract

The decapeptide gonadotropin-releasing hormone, also referred to as luteinizing hormone-releasing hormone with the sequence (pGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2) plays an important role in regulating the reproductive system. It stimulates differential release of the gonadotropins FSH and LH from pituitary tissue. To date, treatment of hormone-dependent diseases targeting the GnRH receptor, including peptide GnRH agonist and antagonists are now available on the market. The inherited issues associate with peptide agonists and antagonists have however, led to significant interest in developing orally active, small molecule, non-peptide antagonists. In this review, we will summarize all developed small molecule GnRH antagonists along with the most recent clinical data and therapeutic applications.

Cite

CITATION STYLE

APA

Tukun, F. L., Olberg, D. E., Riss, P. J., Haraldsen, I., Kaass, A., & Klaveness, J. (2017, December 1). Recent development of non-peptide GnRH antagonists. Molecules. MDPI AG. https://doi.org/10.3390/molecules22122188

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free